RIGL – Rigel Pharmaceuticals, Inc.
Float Short %
14.4
Margin Of Safety %
-14
Put/Call OI Ratio
0.25
EPS Next Q Diff
-2.61
EPS Last/This Y
3.92
EPS This/Next Y
-1.6
Price
41.46
Target Price
41.2
Analyst Recom
2.2
Performance Q
110.34
Relative Volume
2.3
Beta
1.17
Ticker: RIGL
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-25 | RIGL | 20.16 | 0.18 | 0.96 | 1128 |
| 2025-07-28 | RIGL | 20.01 | 0.20 | 0.17 | 1172 |
| 2025-07-29 | RIGL | 19.86 | 0.20 | 3.11 | 1193 |
| 2025-07-30 | RIGL | 21.04 | 0.23 | 1.09 | 1222 |
| 2025-07-31 | RIGL | 21.05 | 0.26 | 0.04 | 1282 |
| 2025-08-01 | RIGL | 21.88 | 0.25 | 0.34 | 1301 |
| 2025-08-04 | RIGL | 22.71 | 0.26 | 0.10 | 1372 |
| 2025-08-05 | RIGL | 24.3 | 0.21 | 0.06 | 1576 |
| 2025-08-06 | RIGL | 29.77 | 0.14 | 0.02 | 2853 |
| 2025-08-07 | RIGL | 30.43 | 0.21 | 0.22 | 2128 |
| 2025-08-08 | RIGL | 31.67 | 0.22 | 0.14 | 2250 |
| 2025-08-11 | RIGL | 33.43 | 0.22 | 0.04 | 2326 |
| 2025-08-12 | RIGL | 34.52 | 0.22 | 0.08 | 2485 |
| 2025-08-13 | RIGL | 36.34 | 0.22 | 0.45 | 2553 |
| 2025-08-14 | RIGL | 37.95 | 0.29 | 0.47 | 2845 |
| 2025-08-15 | RIGL | 39.5 | 0.32 | 0.35 | 3004 |
| 2025-08-18 | RIGL | 40.03 | 0.27 | 0.43 | 2068 |
| 2025-08-19 | RIGL | 38.89 | 0.28 | 0.41 | 2770 |
| 2025-08-20 | RIGL | 41.28 | 0.29 | 0.29 | 2880 |
| 2025-08-21 | RIGL | 41.92 | 0.26 | 0.12 | 3045 |
| 2025-08-22 | RIGL | 41.49 | 0.25 | 0.26 | 3182 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-25 | RIGL | 20.17 | 2441.7 | 32.3 | 2.26 |
| 2025-07-28 | RIGL | 19.94 | 2441.7 | 32.3 | 2.26 |
| 2025-07-29 | RIGL | 19.90 | 2441.7 | 33.0 | 2.26 |
| 2025-07-30 | RIGL | 21.01 | 2441.7 | 37.9 | 2.26 |
| 2025-07-31 | RIGL | 21.06 | 2441.7 | 33.5 | 2.26 |
| 2025-08-01 | RIGL | 21.91 | 2441.7 | 36.6 | 2.26 |
| 2025-08-04 | RIGL | 22.67 | 2441.7 | 36.2 | 2.26 |
| 2025-08-05 | RIGL | 24.24 | 2441.7 | 39.0 | 2.26 |
| 2025-08-06 | RIGL | 29.83 | 2441.7 | 52.3 | 2.26 |
| 2025-08-07 | RIGL | 30.44 | 2441.7 | -25.7 | 2.26 |
| 2025-08-08 | RIGL | 31.70 | 2441.7 | 13.5 | 4.77 |
| 2025-08-11 | RIGL | 33.44 | 5.1 | 15.1 | 4.77 |
| 2025-08-12 | RIGL | 34.49 | 5.1 | 12.1 | 4.77 |
| 2025-08-13 | RIGL | 36.58 | 5.1 | 15.7 | 4.77 |
| 2025-08-14 | RIGL | 37.89 | 5.1 | 12.7 | 4.77 |
| 2025-08-15 | RIGL | 39.50 | 5.1 | 13.4 | 4.91 |
| 2025-08-18 | RIGL | 40.02 | 13.3 | 9.7 | 4.91 |
| 2025-08-19 | RIGL | 38.94 | 13.3 | 4.7 | 4.91 |
| 2025-08-20 | RIGL | 41.33 | 13.3 | 15.8 | 4.91 |
| 2025-08-21 | RIGL | 42.03 | 13.3 | 10.1 | 4.91 |
| 2025-08-22 | RIGL | 41.46 | 13.3 | 6.7 | 4.91 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-25 | RIGL | -3.82 | 16.44 | 13.77 |
| 2025-07-28 | RIGL | -3.82 | 15.73 | 13.77 |
| 2025-07-29 | RIGL | -3.82 | 15.73 | 13.77 |
| 2025-07-30 | RIGL | -3.82 | 15.73 | 13.77 |
| 2025-07-31 | RIGL | -3.82 | 15.73 | 13.77 |
| 2025-08-01 | RIGL | -3.82 | 15.73 | 13.77 |
| 2025-08-04 | RIGL | -3.82 | 16.72 | 13.77 |
| 2025-08-05 | RIGL | -3.82 | 16.72 | 13.77 |
| 2025-08-06 | RIGL | -3.82 | 16.72 | 13.77 |
| 2025-08-07 | RIGL | 0.00 | 16.72 | 13.77 |
| 2025-08-08 | RIGL | 0.00 | 16.72 | 13.72 |
| 2025-08-11 | RIGL | 0.00 | 17.15 | 13.72 |
| 2025-08-12 | RIGL | 0.00 | 17.15 | 14.40 |
| 2025-08-13 | RIGL | 0.00 | 17.15 | 14.40 |
| 2025-08-14 | RIGL | 0.00 | 17.15 | 14.40 |
| 2025-08-15 | RIGL | 0.00 | 17.15 | 14.40 |
| 2025-08-18 | RIGL | 0.00 | 9.49 | 14.40 |
| 2025-08-19 | RIGL | 0.00 | 9.49 | 14.40 |
| 2025-08-20 | RIGL | 0.00 | 9.49 | 14.40 |
| 2025-08-21 | RIGL | 0.00 | 9.49 | 14.40 |
| 2025-08-22 | RIGL | 0.00 | 9.49 | 14.40 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
3.28
Avg. EPS Est. Current Quarter
0.79
Avg. EPS Est. Next Quarter
0.67
Insider Transactions
Institutional Transactions
9.49
Beta
1.17
Average Sales Estimate Current Quarter
61
Average Sales Estimate Next Quarter
64
Fair Value
35.82
Quality Score
99
Growth Score
42
Sentiment Score
91
Actual DrawDown %
24.6
Max Drawdown 5-Year %
-86.4
Target Price
41.2
P/E
7.67
Forward P/E
11.46
PEG
0.14
P/S
2.78
P/B
9.09
P/Free Cash Flow
11.31
EPS
5.41
Average EPS Est. Cur. Y
4.91
EPS Next Y. (Est.)
3.31
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
36.51
Relative Volume
2.3
Return on Equity vs Sector %
94.7
Return on Equity vs Industry %
107.6
EPS 1 7Days Diff
2.7
EPS 1 30Days Diff
2.66
EBIT Estimation
6.7
Rigel Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 162
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
stock quote shares RIGL – Rigel Pharmaceuticals, Inc. Stock Price stock today
news today RIGL – Rigel Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RIGL – Rigel Pharmaceuticals, Inc. yahoo finance google finance
stock history RIGL – Rigel Pharmaceuticals, Inc. invest stock market
stock prices RIGL premarket after hours
ticker RIGL fair value insiders trading